Tracon pharmaceuticals, inc. (TCON)
Balance Sheet / Yearly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14
Assets
Current assets:
Cash and cash equivalents

14,134

16,412

19,053

26,336

22,085

25,136

28,193

34,434

62,493

29,467

32,864

26,001

32,221

35,710

29,648

34,020

43,265

41,373

47,152

61,164

65,291

35,000

Short-term investments

-

-

0

0

9,984

13,968

18,978

18,933

0

4,999

3,000

5,997

4,498

8,703

5,465

2,137

2,225

10,783

10,503

-

-

-

Prepaid and other assets

835

848

1,217

594

1,019

1,499

1,268

1,494

1,302

1,591

1,441

814

1,126

1,235

1,395

1,570

1,305

1,150

2,204

4,315

1,679

728

Total current assets

14,969

17,260

20,270

26,930

33,088

40,603

48,439

54,861

63,795

36,057

37,305

32,812

37,845

45,648

36,508

37,727

46,795

53,306

59,859

65,479

66,970

35,728

Property and equipment, net

19

23

27

32

38

45

52

59

66

73

71

78

75

82

106

128

152

173

141

143

91

97

Other assets

760

838

915

989

1,061

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

43

43

43

40

40

40

2,346

Total assets

15,748

18,121

21,212

27,951

34,187

40,648

48,491

54,920

63,861

36,130

37,376

32,890

37,920

45,730

36,614

37,898

46,990

53,522

60,040

65,662

67,101

38,171

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued expenses

6,911

7,875

9,204

10,466

11,034

10,947

12,062

10,511

12,480

6,800

6,505

6,536

5,702

6,213

6,697

6,600

8,607

8,281

-

-

-

3,166

Accrued compensation and related expenses

594

1,355

1,056

937

714

1,464

1,156

821

1,733

1,494

1,325

1,096

932

1,588

1,188

979

785

1,163

-

-

-

808

Current portion of deferred revenue

-

-

-

-

-

-

-

-

-

667

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,990

6,097

3,524

-

Current portion of deferred revenue

-

-

-

-

-

-

-

-

-

-

-

386

871

1,259

1,749

2,186

2,389

3,353

4,320

4,789

4,527

4,357

Preferred stock warrant liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

246

Long-term debt, current portion

1,267

2,604

2,570

2,536

1,806

1,084

370

-

533

2,837

1,994

1,162

343

333

3,536

3,471

2,417

1,378

321

-

4,749

4,676

Final payment due bank

-

-

-

-

-

-

-

-

320

-

-

-

-

850

-

-

-

-

-

-

-

-

Total current liabilities

8,772

11,834

12,830

13,939

13,554

13,495

13,588

11,332

15,066

11,798

9,824

9,180

7,848

10,243

13,170

13,236

14,198

14,175

11,631

10,886

12,800

13,253

Deferred revenue

-

-

-

-

-

-

-

-

-

2,333

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

400

1,570

2,546

Other long-term liabilities

754

850

945

1,036

1,124

368

371

372

93

409

407

372

337

21

874

877

-

905

-

-

-

-

Other long-term liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

886

-

748

773

522

408

Long-term debt, less current portion

3,438

2,739

3,402

4,057

4,704

5,343

5,973

6,258

6,213

4,603

5,329

6,043

6,747

7,130

4,786

5,694

6,586

7,464

6,601

6,812

3,043

4,258

Commitments and contingencies (Note 4)

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

-

-

-

-

Redeemable convertible preferred stock, $0.001 par value; authorized sharesnone and 24,900,000 at December 31, 2015 and December 31, 2014, respectively; issued and outstanding sharesnone and 24,650,273 at December 31, 2015 and December 31, 2014, respectively; liquidation preference of $0 and $51,700 at December 31, 2015 and December 31, 2014, respectively

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

49,880

Stockholders’ equity:
Preferred stock, $0.001 par value, authorized shares — 10,000,000 at March 31, 2020 and December 31, 2019; issued and outstanding shares — none

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

-

Common stock, $0.001 par value; authorized shares — 20,000,000 at March 31, 2020 and December 31, 2019; issued and outstanding shares — 5,497,938 and 4,051,187 at March 31, 2020 and December 31, 2019, respectively

5

4

30

30

30

3

30

30

28

18

17

17

17

16

13

12

12

12

12

12

12

2

Additional paid-in capital

169,134

165,028

162,403

162,088

161,648

161,099

160,433

159,747

155,526

121,670

119,940

116,589

115,716

113,918

97,055

91,492

90,424

89,556

88,591

87,875

87,329

2,004

Accumulated deficit

-166,355

-162,334

-158,398

-153,199

-146,873

-139,660

-131,904

-122,819

-113,065

-104,701

-98,141

-99,311

-92,745

-85,598

-79,284

-73,413

-65,116

-58,590

-47,543

-41,096

-38,175

-34,180

Total stockholders’ equity

2,784

2,698

4,035

8,919

14,805

21,442

28,559

36,958

42,489

16,987

21,816

17,295

22,988

28,336

17,784

18,091

25,320

30,978

41,060

46,791

49,166

-32,174

Total liabilities and stockholders’ equity

15,748

18,121

21,212

27,951

34,187

40,648

48,491

54,920

63,861

36,130

37,376

32,890

37,920

45,730

36,614

37,898

46,990

53,522

60,040

65,662

67,101

38,171